Form 4: Fulcrum Therapeutics VP of Finance Sells Shares
SEC Form 4 Filing
Gregory Tourangeau, VP of Finance at Fulcrum Therapeutics, sold 4,884 shares of common stock at an average price of $11.7155 on March 8, 2024.
Summary
- On March 8, 2024, Gregory Tourangeau, the Vice President of Finance at Fulcrum Therapeutics, sold 4,884 shares of the company's common stock.
- The shares were sold at a weighted average price of $11.7155.
- The price range for the sales was between $11.71 and $11.74.
- Following the transaction, Tourangeau directly owns 11,807 shares of Fulcrum Therapeutics.
- This includes 699 shares acquired under the Issuer's employee stock purchase plan on May 13, 2022.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard Form 4 filing indicating a sale of shares by an officer. It doesn't inherently suggest positive or negative outlook for the company.
Industry Context
This is a routine disclosure of insider trading activity. It's common for executives to periodically sell shares for personal financial management.
Stakeholder Impact
- The sale of shares by a company officer could be perceived negatively by some investors, potentially leading to a slight decrease in stock price in the short term.
Key Dates
| Date | Description |
|---|---|
| 05/13/2022 | 699 shares acquired under the Issuer's employee stock purchase plan |
| 03/08/2024 | Gregory Tourangeau sold 4,884 shares of Fulcrum Therapeutics common stock |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.